MX386151B - Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. - Google Patents

Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.

Info

Publication number
MX386151B
MX386151B MX2016002308A MX2016002308A MX386151B MX 386151 B MX386151 B MX 386151B MX 2016002308 A MX2016002308 A MX 2016002308A MX 2016002308 A MX2016002308 A MX 2016002308A MX 386151 B MX386151 B MX 386151B
Authority
MX
Mexico
Prior art keywords
multiple myeloma
trichostatin
tsa
treatment
individual
Prior art date
Application number
MX2016002308A
Other languages
English (en)
Other versions
MX2016002308A (es
Inventor
Christian Lavedan
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2016002308A publication Critical patent/MX2016002308A/es
Publication of MX386151B publication Critical patent/MX386151B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere en general al tratamiento del mieloma múltiple. Una modalidad de la invención proporciona un método para tratar el mieloma múltiple (MM) en un individuo, comprendiendo el método: administrar al individuo una cantidad eficaz de tricostatina A (TSA).
MX2016002308A 2013-08-22 2014-08-22 Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. MX386151B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US201361870747P 2013-08-27 2013-08-27
PCT/US2014/052216 WO2015027125A1 (en) 2013-08-22 2014-08-22 Multiple myeloma treatment

Publications (2)

Publication Number Publication Date
MX2016002308A MX2016002308A (es) 2016-06-15
MX386151B true MX386151B (es) 2025-03-18

Family

ID=51492478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002308A MX386151B (es) 2013-08-22 2014-08-22 Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.

Country Status (13)

Country Link
US (5) US20160199324A1 (es)
EP (2) EP3623011B1 (es)
JP (4) JP2016534115A (es)
KR (6) KR20220153684A (es)
CN (2) CN113244205A (es)
AU (1) AU2014308704B2 (es)
BR (1) BR112016003609B1 (es)
CA (2) CA3171302A1 (es)
CL (2) CL2016000396A1 (es)
EA (1) EA037638B1 (es)
ES (2) ES2754199T3 (es)
MX (1) MX386151B (es)
WO (1) WO2015027125A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3616754A1 (en) 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
KR20220153684A (ko) * 2013-08-22 2022-11-18 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
PL3651766T3 (pl) 2017-07-10 2025-03-03 Celgene Corporation 4-(4-(4-(((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-4-ylo)oksy)metylo)benzylo)piperazyn-1-ylo)-3-fluorobenzonitryl jako związek przeciwproliferacyjny
CN109913420A (zh) * 2019-03-07 2019-06-21 北京师范大学 Cdc20共表达基因网络作为胶质瘤治疗靶点的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US20020183388A1 (en) 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
CA3142853A1 (en) * 2004-05-21 2005-12-08 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
ZA200809956B (en) * 2006-05-26 2010-07-28 Celgene Corp Methods and compositions using Immunomodulatory compounds in combination therapy
EP2356255A2 (en) * 2008-12-05 2011-08-17 The Institute of Cancer Research : The Royal Cancer Hospital Methods for determining a prognosis in multiple myeloma
EP3616754A1 (en) * 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
KR20220153684A (ko) * 2013-08-22 2022-11-18 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Also Published As

Publication number Publication date
JP2020073508A (ja) 2020-05-14
ES2754199T3 (es) 2020-04-16
KR20170126019A (ko) 2017-11-15
US20180256521A1 (en) 2018-09-13
CL2018001719A1 (es) 2018-07-27
BR112016003609B1 (pt) 2021-04-27
KR20200011554A (ko) 2020-02-03
WO2015027125A1 (en) 2015-02-26
CA3171302A1 (en) 2015-02-26
US20160199324A1 (en) 2016-07-14
ES3018607T3 (es) 2025-05-16
JP2016534115A (ja) 2016-11-04
MX2016002308A (es) 2016-06-15
KR102373721B1 (ko) 2022-03-11
US11737993B2 (en) 2023-08-29
EP3036006A1 (en) 2016-06-29
CN105579100A (zh) 2016-05-11
US20200009087A1 (en) 2020-01-09
KR20220035275A (ko) 2022-03-21
US20240342120A1 (en) 2024-10-17
KR102465000B1 (ko) 2022-11-09
EP3623011A1 (en) 2020-03-18
EA201690446A1 (ru) 2016-06-30
EP3623011B1 (en) 2025-02-12
KR20160033780A (ko) 2016-03-28
NZ716669A (en) 2021-03-26
JP2023179435A (ja) 2023-12-19
EA037638B1 (ru) 2021-04-23
CA2921037A1 (en) 2015-02-26
AU2014308704A1 (en) 2016-02-25
CL2016000396A1 (es) 2017-03-17
CA2921037C (en) 2022-11-15
JP7698680B2 (ja) 2025-06-25
EP3036006B1 (en) 2019-10-09
KR20220153684A (ko) 2022-11-18
US20230346719A1 (en) 2023-11-02
AU2014308704B2 (en) 2019-10-10
CN113244205A (zh) 2021-08-13
KR20210021602A (ko) 2021-02-26
JP2022017337A (ja) 2022-01-25

Similar Documents

Publication Publication Date Title
PH12015502075A1 (en) Treatment of cataplexy
MX386598B (es) Compuestos antibacterianos.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX380689B (es) Tratamiento de cancer con dihidropirazino-pirazinas.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201692534A1 (ru) Способы лечения гипотонии
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
BR112016012248A2 (pt) método de tratamento de nefropatia
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
EA201491581A1 (ru) Везикулярные композиции
AR102871A1 (es) Métodos de tratamiento de fibrosis
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX374354B (es) Método de curación de heridas.
BR112016014099A2 (pt) método de tratamento de feridas
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης